drugset / Trial / NCT05468294
F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer
NaSequentialOpen-labelTreatment
Summary
Prospective, open label, non-randomized, phase I/IIb study of F16IL2 in combination with Nivolumab.
Timeline
- Start
- 2017-03-09
- Primary completion
- 2021-12-31
- Completion
- 2022-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F16IL2 | Protein / enzyme biologic | 15 iu | Intravenous |
| Subject | F16IL2 | Protein / enzyme biologic | 30 iu | Intravenous |
| Subject | F16IL2 | Protein / enzyme biologic | 50 iu | Intravenous |
| Subject | F16IL2 | Protein / enzyme biologic | 70 iu | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |